1009 Results

People

  1. Motzer
    Motzer
  2. O'Reilly
    O'Reilly
  3. Kris
    Kris
  4. Aghajanian
    Aghajanian
  5. Hudis
    Hudis
  6. Bajorin
    Bajorin
  7. Kelsen
    Kelsen
  8. Ginsberg
    Ginsberg
  9. Krug
    Krug
  10. Scher
    Scher

Groups

  1. Department of Medicine (716)
  2. Solid Tumor Oncology Division (483)
  3. Hematologic Malignancies, Division of (277)
  4. Center for Hematologic Malignancies (224)
  5. Survivorship Research (151)
  6. Genitourinary Oncology Service (136)
  7. Epidemiology and Biostatistics (119)
  8. Radiology, Department of (111)
  9. Biostatistics Service (109)
  10. GSK Faculty (104)
  1. "anemia"
Formats
  1. Journal Article (926)
  2. Review (42)
  3. Research Letter (15)
  4. Conference Paper (12)
  5. Editorial (4)
  6. Guidelines (3)
  7. Miscellaneous (3)
  8. Correspondence (2)
  9. Book Section (1)
  10. Meeting Abstract (1)
Groups
  1. Department of Medicine (716)
  2. Solid Tumor Oncology Division (483)
  3. Hematologic Malignancies, Division of (277)
  4. Center for Hematologic Malignancies (224)
  5. Survivorship Research (151)
  6. Genitourinary Oncology Service (136)

More Groups

People
  1. Robert Motzer (55)
  2. Eileen O'Reilly (35)
  3. Mark Kris (32)
  4. Carol Aghajanian (31)
  5. Clifford Hudis (31)
  6. Dean Bajorin (29)

More People

Years
  1. 2025 (41)
  2. 2024 (99)
  3. 2023 (56)
  4. 2022 (45)
  5. 2021 (25)
  6. 2020 (62)

More Years

Publications
  1. Journal of Clinical Oncology (69)
  2. Cancer (50)
  3. Clinical Cancer Research (49)
  4. Lancet Oncology (47)
  5. Gynecologic Oncology (34)
  6. Blood (29)

More Publications

Publishers
  1. Elsevier Inc. (147)
  2. Springer (90)
  3. Elsevier Science, Inc. (83)
  4. American Society of Clinical Oncology (74)
  5. Wiley Blackwell (65)
  6. Nature Publishing Group (61)

More Publishers

Results (1009)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
    Journal Article

    Rathkopf, D. E.; Patel, M. R.; Choudhury, A. D.; Rasco, D.; Lakhani, N.; Hawley, J. E.; Srinivas, S.; Aparicio, A.; Narayan, V.; Runcie, K. D.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: A phase I trial
    Journal Article

    Gounder, M.; Johnson, M.; Heist, R. S.; Shapiro, G. I.; Postel-Vinay, S.; Wilson, F. H.; Garralda, E.; Wulf, G.; Almon, C.; Nabhan, S.; more...
    Nature Communications (2025)

    Fulltext@MSK | Save
  • New treatments for adult T-cell leukemia/lymphoma
    Review

    Epstein-Peterson, Z. D.; Gurumurthi, A.; Horwitz, S. M.
    Leukemia Research (2025)

    Fulltext@MSK | Save
  • Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study
    Journal Article

    Sangro, B.; Kudo, M.; Erinjeri, J. P.; Qin, S.; Ren, Z.; Chan, S. L.; Arai, Y.; Heo, J.; Mai, A.; Escobar, J.; more...
    Lancet (2025)

    Fulltext@MSK | Save
  • Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: A phase 1, first-in-human trial
    Journal Article

    Ghobadi, A.; Bachanova, V.; Patel, K.; Park, J. H.; Flinn, I.; Riedell, P. A.; Bachier, C.; Diefenbach, C. S.; Wong, C.; Bickers, C.; more...
    Lancet (2025)

    Fulltext@MSK | Save
  • Effectiveness and safety of combined treatment with herbal medicines and palliative chemotherapy for advanced gastric cancer: A systematic review, and meta-analysis
    Review

    Kim, D. H.; Kim, S. D.; Jun, H. J.; Kwag, E. B.; Shin, S. W.; Yoo, H. S.; Park, S. J.
    Integrative Medicine Research (2025)

    Fulltext@MSK | Save
  • Impact of recent translational and therapeutic developments on clinical course of BCR::ABL1-positive and -negative myeloproliferative neoplasms
    Review

    Mughal, T. I.; Mascarenhas, J.; Rampal, R. K.; Bose, P.; Lion, T.; Ajufo, H.; Yacoub, A.; Meshinchi, S.; Masarova, L.; Mesa, R.; more...
    Hematological Oncology (2025)

    Fulltext@MSK | Save
  • Phase II study of palbociclib in patients with tumors with CDK4 or CDK6 amplification: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1C
    Journal Article

    O’Hara, M. H.; Jegede, O.; Dickson, M. A.; DeMichele, A. M.; Piekarz, R.; Gray, R. J.; Wang, V.; McShane, L. M.; Rubinstein, L. V.; Patton, D. R.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis
    Journal Article

    Liu, Y. L.; Mathews, C. A.; Simpkins, F.; Cadoo, K. A.; Provencher, D.; McCormick, C. C.; ElNaggar, A. C.; Altman, A. D.; Gilbert, L.; Black, D.; more...
    Cancer (2025)

    Fulltext@MSK | Save
  • A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
    Journal Article

    Hughes, B. G. M.; Guminski, A.; Bowyer, S.; Migden, M. R.; Schmults, C. D.; Khushalani, N. I.; Chang, A. L. S.; Grob, J. J.; Lewis, K. D.; Ansstas, G.; more...
    Journal of the American Academy of Dermatology (2025)

    Fulltext@MSK | Save